Don't judge early-stage biotech Moderna on its stock's post-IPO drop: Cramer By: CNBC.com News December 10, 2018 at 18:35 PM EST Jim Cramer says there's more to Wall Street newcomer Moderna than the action in the biotechnology company's stock. Read More >> Related Stocks: Astrazeneca Plc ADR Ionis Pharmaceuticals Moderna Inc Renaissance IPO ETF